ATVB|PVD 2017 Programming

Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease

May 4 – 6, 2017
Hyatt Regency Minneapolis | Minneapolis, Minn.
Preliminary Program

Our ATVB|PVD 2017 Preliminary Program is now online: download and view the PDF now.


About This Meeting

The ATVB/PVD 2017 Scientific Sessions is sponsored by the Council on Arteriosclerosis, Thrombosis and Vascular Biology and the Peripheral Vascular Disease Council, in cooperation with the Council on Functional Genomics and Translational Biology, and the Society for Vascular Surgery. This meeting provides unique opportunities to meet with colleagues from around the world with wide-ranging research interests and expertise within the research communities of arteriosclerosis, thrombosis, vascular biology. The primary goal of this conference is to provide a forum for the timely exchange of information about new and emerging scientific research in lipids and lipoproteins, arteriosclerosis, thrombosis, vascular biology, genomics and peripheral vascular disease.

One of the areas of emphasis for this conference is to encourage interactions between young scientists and more senior scientists in their research area to foster dialogue and facilitate the exchange of ideas. The format of the conference, with many invited presentations as well as a dedicated focus on poster presentations, is intended to maximize a thought-provoking flow of information and discourse among scientists.

Target Audience

The target audience includes scientists and clinicians in:
  • Cardiovascular medicine
  • Cardiovascular surgery
  • Cardiovascular research
  • Thrombosis research
  • Clinical cardiology

 

  • Molecular/cellular biology
  • Vascular biology
  • Vascular medicine
  • Vascular surgery
  • Endocrinology

 

  • Genetics
  • Functional genomics
  • Hematology
  • Immunology
  • Physiology

Learning Objectives

  1. Describe recent findings regarding the role and mechanism of action of TGRL in cardiovascular disease, approaches to assess TGRL proteins, the results of large genetic studies implicating TGRL in atherosclerosis, and the clinical relevance of this research.
     
  2. Evaluate recent research related to HDL-C mechanisms in CVD, including HDL-C function assessment and implications for the prevention and treatment of atherosclerosis.
     
  3. Review the latest research into the signaling and genetic pathways involved in vascular dysfunction; the implications of such research for new therapeutic options and management.
     
  4. Describe current efforts to reverse atherosclerotic damage through medical therapy and vascular regeneration.
     
  5. Identify novel genomic and circulating biomarkers that could be used to assess CVD risk and discuss the strengths and weaknesses of each.
     
  6. Describe the biology of cardio-metabolic pathways and risk factors as they relate to the development and progression of cardiovascular disease and diabetes, and potential options for management.
     
  7. Review novel mechanisms and emerging antithrombotics that reduce atherothrombosis without increasing the bleeding risk.